Brokerages Anticipate OptimizeRx Co. (OPRX) to Post $0.00 Earnings Per Share

Shares of OptimizeRx Co. (NASDAQ:OPRX) have been given an average broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy rating.

Analysts have set a 1-year consensus price objective of $22.50 for the company, according to Zacks. Zacks has also assigned OptimizeRx an industry rank of 68 out of 256 based on the ratings given to its competitors.

Several equities research analysts have recently weighed in on OPRX shares. Lake Street Capital increased their target price on shares of OptimizeRx to $18.00 and gave the company a “buy” rating in a research note on Monday, September 17th. Roth Capital increased their target price on shares of OptimizeRx from $22.50 to $25.00 and gave the company a “buy” rating in a research note on Friday, September 28th. Zacks Investment Research downgraded shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 10th. Finally, William Blair started coverage on shares of OptimizeRx in a research note on Thursday, January 3rd. They issued an “outperform” rating on the stock.

A hedge fund recently bought a new stake in OptimizeRx stock. Vanguard Group Inc bought a new stake in OptimizeRx Co. (NASDAQ:OPRX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 289,123 shares of the company’s stock, valued at approximately $5,204,000. Vanguard Group Inc owned 2.41% of OptimizeRx at the end of the most recent quarter. Institutional investors own 33.72% of the company’s stock.

OptimizeRx stock opened at $12.20 on Tuesday. The firm has a market cap of $159.67 million, a P/E ratio of -58.10, a price-to-earnings-growth ratio of 2.85 and a beta of 0.92. OptimizeRx has a 52-week low of $2.30 and a 52-week high of $18.39.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings results on Monday, November 5th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.01 by $0.01. OptimizeRx had a net margin of 0.54% and a return on equity of 0.87%. The company had revenue of $5.42 million for the quarter, compared to the consensus estimate of $5.28 million. As a group, equities analysts forecast that OptimizeRx will post 0.03 EPS for the current year.

About OptimizeRx

OptimizeRx Corporation provides digital health messaging to the pharmaceutical industry. The company offers a direct channel for pharmaceutical companies to communicate with healthcare providers. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-Prescribe systems to search, print, or electronically dispense directly to patients, as well as a network of pharmacies; and brand messaging services, such as various brand awareness and clinical messaging services consisting of brand awareness messages, reminder ads, clinical messages, and unbranded messages that could be targeted by specialty, diagnostic code, and other criteria.

Featured Story: What is the S&P 500 Index?

Get a free copy of the Zacks research report on OptimizeRx (OPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit